EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING 16 WEEKS’ EXTENDED INDUCTION TREATMENT FOLLOWED BY 52 WEEKS’ MAINTENANCE TREATMENT IN THE U-ACHIEVE/U-ACCOMPLISH TRIALS

Remo Panaccione  ¹     Silvio Danese  ²     Wen Zhou  ³     Justin Klaff     Dapo Ilo     Xuan Yao     Gweneth Levy     Peter D.R. Higgins  ⁴     Edward V. Loftus Jr.  ⁵     Severine Vermeire  ^6    
1 University of Calgary, Calgary, Canada
² IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy
³ AbbVie Inc., North Chicago, United States
⁴ University of Michigan, Ann Arbor, United States
⁵ Mayo Clinic, College of Medicine & Science, Rochester
⁶ University Hospital Leuven & KU Leuven, Leuven

Session
IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)